{"entity":{"id":"paper-seekincare-j-mol-diagn-2025","kind":"paper","name":"Clinical Validation of a Noninvasive Multi-Omics Method for Multicancer Early Detection in Retrospective and Prospective Cohorts","aka":[],"tldr":"SeekIn's combined DNA and protein test found six in ten cancers in a laboratory set and seven in ten in people who had bought it, at specificities of 95 to 98 per cent.","summary":"Li and colleagues report SeekInCare, which combines copy number, fragment size, end motif and oncogenic virus signals from shallow whole-genome sequencing of cell-free DNA with seven protein tumour markers. In a retrospective set of 617 patients with 27 cancer types and 580 without cancer it reached 60.0% sensitivity at 98.3% specificity (area under the curve 0.899), with 37.7%, 50.4%, 66.7% and 78.1% at stages I to IV. In a prospective cohort of 1,203 people who received it as a laboratory-developed test (median follow-up 753 days) it had 70.0% sensitivity at 95.2% specificity.","asOf":"2026-10-29","links":[{"label":"Journal of Molecular Diagnostics 2025","url":"https://doi.org/10.1016/j.jmoldx.2025.04.001"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40311780/"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","fragmentomics","proteomics"],"targets":[],"drugs":["seekincare"],"companies":["seekin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"The Journal of Molecular Diagnostics","year":2025,"doi":"10.1016/j.jmoldx.2025.04.001","pmid":"40311780","authors":"Li S, Geng S, Chen Y, et al.","paperType":"observational","findings":["Retrospective: 60.0% sensitivity at 98.3% specificity; stage I 37.7%.","Prospective (1,203 people): 70.0% sensitivity at 95.2% specificity."],"whatItMeans":"One of few multi-cancer tests with a stage I figure above one in three, from a case-control set; the prospective figures rest on few cancers.","caveats":["The prospective cohort's number of cancers is not given in the abstract.","Authors include SeekIn staff."],"changedPractice":false,"participants":2400},"route":"/key-papers/paper-seekincare-j-mol-diagn-2025/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"drug":[{"id":"seekincare","kind":"drug","name":"SeekInCare","route":"/drugs/seekincare/"}],"company":[{"id":"seekin","kind":"company","name":"SeekIn","route":"/companies/seekin/"}]}}